-
公开(公告)号：EP3329911A1
公开(公告)日：2018-06-06
申请号：EP17209015.1
申请日：2009-09-18
申请人： Pfizer Inc.
IPC分类号： A61K31/198 , A61K47/18 , A61K47/26 , A61K9/00 , A61K39/395
CPC分类号： A61K9/0019 , A61K31/198 , A61K47/183 , A61K47/26
摘要： The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by a liquid formulation of a humanised anti-NGF antibody.
-
公开(公告)号：EP2331090A1
公开(公告)日：2011-06-15
申请号：EP09787253.5
申请日：2009-09-18
申请人： Pfizer Inc.
IPC分类号： A61K31/198 , A61K47/18 , A61K47/26 , A61K9/00 , A61K39/395
CPC分类号： A61K9/0019 , A61K31/198 , A61K47/183 , A61K47/26
摘要： The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by a liquid formulation of a humanised anti-NGF antibody.
摘要翻译： 本发明一般涉及抗体的药物制剂领域。 具体地说，本发明涉及稳定的液体抗体制剂及其药物制剂和用途。 本发明以人源化抗NGF抗体的液体制剂为例。
-
公开(公告)号：EP2331090B1
公开(公告)日：2018-01-03
申请号：EP09787253.5
申请日：2009-09-18
申请人： Pfizer Inc.
IPC分类号： A61K31/198 , A61K47/18 , A61K47/26 , A61K9/00 , A61K39/395
CPC分类号： A61K9/0019 , A61K31/198 , A61K47/183 , A61K47/26
摘要： The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by a liquid formulation of a humanised anti-NGF antibody.
-
-
搜索结果
3 条记录 (耗时 0.011 秒)
